The introduction of combination antiretroviral therapy (ART) has dramatically increased the life expectancy of persons living with human immunodeficiency virus (HIV). However, despite sustained ART-mediated suppression of viral replication, HIV-infected persons still have higher risks of serious non-AIDS diseases (eg, cardiovascular disease) and AIDS-defining cancers and higher all-cause mortality rates, compared with HIV-uninfected individuals \[[@CIT0001]\]. Persistent immune dysregulation through systemic inflammation and immune activation is thought to be a key contributor, driven by multiple factors, including microbial translocation, residual low-level viral replication, and coinfections \[[@CIT0001]\].

Evidence from Europe and North America suggests that suppressive ART may reduce some plasma biomarkers of HIV-related immune activation, such as interleukin 6 (IL-6), C-reactive protein (CRP), C-X-C chemokine ligand 10 (CXCL10), and soluble scavenger receptor CD14 (sCD14), but not necessarily to levels present in HIV-uninfected individuals, especially when ART is initiated during severe immunodeficiency (CD4^+^ T-cell count \<200/μL) \[[@CIT0002]\]. Data from sub-Saharan Africa, where ART is generally started late and pathogen exposure is high, are limited \[[@CIT0003]\].

The current study sought to investigate (1) the biomarker profiles of HIV-related immune activation in a well-characterized multicountry African adult cohort with advanced HIV infection, (2) the extent to which fully suppressive ART mitigates immune activation, and (3) factors associated with residual immune activation.

METHODS {#s1}
=======

Study Population {#s2}
----------------

Pan-African Studies to Evaluate Resistance Monitoring is a multicountry cohort of HIV-1--infected adults (aged ≥18 years) starting first-line ART (2007--2014), as profiled elsewhere \[[@CIT0006]\]. For the present retrospective analysis, 398 participants were selected from 8 study sites in Kenya, Nigeria, South Africa, Uganda, and Zambia; they had an undetectable (\<50 copies/mL) plasma viral load at month 12 and had paired cryopreserved plasma samples available before ART initiation and after 12 months of first-line nonnucleoside reverse-transcriptase inhibitor--based ART. Stored plasma samples from 90 HIV-uninfected blood bank donors from Nigeria, South, Africa, and Uganda served as a reference group. The protocol was approved by the research ethics committees at all collaborating sites. All participants provided written informed consent, including for sample storage for future testing.

Biomarker Assays {#s3}
----------------

A panel of 8 plasma biomarkers was selected based on their known associations with diminished CD4^+^ T-cell restoration \[[@CIT0007]\], HIV disease progression and/or non-AIDS disease \[[@CIT0001]\]. Levels of sCD14 and soluble CD163 (sCD163), CRP, CXCL10, IL-6, chemokine (C-C motif) ligand 2 (CCL2), C-X-C chemokine ligand 9 (CXCL9) were measured using 2 Luminex assays (Luminex; R&D Systems) and analyzed using BioPlex 200 apparatus and software (Bio-Rad Laboratories). Lipopolysaccharide (LPS)--binding protein (LBP) levels were determined using a DuoSet enzyme-linked immunosorbent assay (R&D Systems). A single lot of assay kits was used, to eliminate interlot variability. All samples were tested in duplicate on the same plate to minimize variability.

Statistical Analysis {#s4}
--------------------

We compared biomarker values in the same HIV-infected participants before and during ART (percentage change), and in the HIV-uninfected reference group, using Wilcoxon signed rank and Mann-Whitney *U* tests. We used multivariable linear regression to compare biomarker values between the 3 groups and to explore factors associated with biomarkers before and during ART. Associations were expressed using coefficients (95% confidence intervals and *P* values) and partial eta squared (ηp^2^), to estimate small (0.01), medium (0.06) or large (0.14) effect sizes \[[@CIT0008]\]. To explore biomarker differences between countries, we performed post hoc pairwise comparisons, adjusted for participant group, age, and sex, with Šidák correction for multiple testing, and hierarchical cluster analysis (heat map) (see Supplementary Data). For values below or above the assay detection limits we used the respective detection limit in the analyses. All analyses were performed using Stata 12 software (StataCorp).

RESULTS {#s5}
=======

Participant Characteristics {#s6}
---------------------------

Of 398 HIV-infected participants, 57.5% were women, with a median (interquartile range \[IQR\]) age of 36 (32--42) years; 92 (23.1%) were from Kenya, 57 (14.3%) from Nigeria, 65 (16.3%) from South Africa, 121 (30.4%) from Uganda, and 63 (15.8%) from Zambia. The median (IQR) CD4^+^ T-cell count was 137/µL (75--205/µL) before ART and 291/µL (216--395/µL) after 12 months of ART. The median (IQR) pre-ART viral load was 5.0 (4.4--5.5) log~10~ copies/mL. At enrollment, 50 (12.6%) participants had active tuberculosis, and 29 (7.3%) were coinfected with hepatitis B virus. Of the 90 HIV-uninfected reference persons, 24.4% were women, with a median (IQR) age of 36 (30--44) years; 29 (32.2%) were from Nigeria, 30 (33.3%) from South Africa, and 31 (34.4%) from Uganda ([Supplementary Table 1](#sup3){ref-type="supplementary-material"}).

Biomarker Values {#s7}
----------------

The levels of all 8 measured biomarkers were significantly higher in HIV-infected participants before ART than in the HIV-uninfected reference group, in unadjusted ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"} and [Supplementary Table 2](#sup4){ref-type="supplementary-material"}) and adjusted ([Figure 1](#F1){ref-type="fig"} and [Supplementary Table 3](#sup5){ref-type="supplementary-material"}) analyses. The median (IQR) decrease in biomarker value, from before to during ART, was greatest for CXCL10 (−25% \[−32% to −18%\]), followed by IL-6 (−17% \[−58% to 0%\]), CXCL9 (−10% \[−17% to −5%\]), CCL2 (−8% \[−16% to −1%\]), LBP (−5% \[−8% to −1%\]), sCD163 (−5% \[−7% to −2%\]), sCD14 (−1% \[−3% to 0%\]), and CRP (−1% \[−10% to 4%) ([Figure 2](#F2){ref-type="fig"}). These biomarker changes were all statistically significant (*P* \< .001; [Supplementary Table 2](#sup4){ref-type="supplementary-material"}). In HIV-infected participants during ART, compared with the HIV-uninfected reference group, levels of CXCL10, LBP, CRP, sCD163, and sCD14 were significantly higher, levels of CXCL9 and CCL2 lower, and levels of IL-6 similar, in both unadjusted and adjusted analyses ([Figure 1](#F1){ref-type="fig"}, [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}, and [Supplementary Table 2](#sup3){ref-type="supplementary-material"}).

![Comparison of each of the immune biomarkers in human immunodeficiency virus (HIV)--infected participants before and during suppressive antiretroviral therapy (ART), relative to the HIV-uninfected reference group. Figure shows the multivariable linear regression analysis, expressed as regression coefficient (*dots*) with the 95% confidence limits (*error bars*), adjusted for sex, age, and country, with HIV-uninfected persons as the reference group. For each biomarker (*x-axis*), the regression coefficient is shown for HIV-infected participants before (*diamonds*) and during (*dots*) ART. Units of measure are as follows: log~10~ picograms per milliliter for C-X-C chemokine ligand 10 (CXCL10), interleukin 6 (IL-6), C-X-C chemokine ligand 9 (CXCL9), and chemokine (C-C motif) ligand 2 (CCL2); log~10~ nanograms per milliliter for lipopolysaccharide-binding protein (LBP), soluble CD163 (sCD163), and soluble CD14 (sCD14); and log~10~ milligrams per milliliter for C-reactive protein (CRP).](jiz252f0001){#F1}

![Changes in biomarkers levels within the same human immunodeficiency virus--infected participants before and during suppressive antiretroviral therapy (ART), expressed as median percentage (*dots*) and interquartile range (*error bars*). Percentage change was calculated as follows: (Value during ART -- Value before ART)/Value before ART × 100%. Abbreviations: CCL2, chemokine (C-C motif) ligand 2; CRP, C-reactive protein; CXCL9, C-X-C chemokine ligand 9; CXCL10, C-X-C chemokine ligand 10; IL-6, interleukin 6; LBP, lipopolysaccharide-binding protein; sCD14, soluble CD14; sCD163, soluble CD163.](jiz252f0002){#F2}

The heat map suggested that CCL2 levels were elevated in participants from South Africa, and LBP levels elevated in participants from Zambia irrespective of HIV and ART status (both relative to the mean level) ([Supplementary Figure 2](#sup2){ref-type="supplementary-material"}). Post hoc pairwise comparisons found CCL2 levels to be higher in South Africa and LBP levels to be higher in Zambia than in the other countries, which was consistent with the heat map, CRP levels to be lower in Zambia than in Uganda and Nigeria, and IL-6 to be lower in South Africa than in Uganda, Nigeria and Kenya (all *P* \< .001) ([Supplementary Table 4](#sup6){ref-type="supplementary-material"}).

Factors Associated With Residual Immune Activation During Suppressive ART {#s8}
-------------------------------------------------------------------------

The set of independent variables tested explained 24%--50% of the variance of each of the biomarkers during ART (*R*^2^) ([Supplementary Table 5](#sup7){ref-type="supplementary-material"}). The pre-ART value of each biomarker was found to be strongly associated with the same biomarker during suppressive ART: IL-6 (coefficient 0.63 log~10~ pg/mL per unit increase; 95% confidence interval, .37--.88; *P* = .005), CXCL9 (0.55 log~10~ pg/mL per unit increase; .18--.92; *P* = .02), sCD14 (0.56 log~10~ ng/mL per unit increase; .14--.98; *P* = .02), LBP (0.53 log~10~ ng/mL per unit increase; .27--.78; *P* = .008), sCD163 (0.50 log~10~ ng/mL per unit increase; .28--.71; *P* = .006), CCL2 (0.36 log~10~ pg/mL per unit increase; .19--.52; *P* = .007), CRP (0.37 log~10~ mg/L per unit increase; .22--.55; *P* = .007), and CXCL10 (0.35 log~10~ pg/mL per unit increase; .31--.39; *P* \< .001) ([Supplementary Table 5](#sup7){ref-type="supplementary-material"}). The effect size (ηp^2^) was estimated to be large for sCD163 (0.431), IL-6 (0.424), LBP (0.374), sCD14 (0.299), CXCL9 (0.213), CXCL10 (0.167), and CCL2 (0.151) and medium for CRP (0.117). The association was found to be statistically significant (*P* \< .05) for some other factors, but all had small estimated effect sizes (ηp^2^ \< 0.06) ([Supplementary Tables 5](#sup7){ref-type="supplementary-material"} and [6](#sup8){ref-type="supplementary-material"}).

Factors Associated With Immune Activation Before ART Initiation {#s9}
---------------------------------------------------------------

The set of independent variables tested explained 4%--28% of the variance of each of the biomarkers before ART (*R*^2^) ([Supplementary Table 7](#sup9){ref-type="supplementary-material"}). High pre-ART viral load was associated with elevated CXCL10 levels (coefficient, 0.13 log~10~ pg/mL per unit increase; 95% CI, .06--.21; *P* = .01), with an estimated medium effect size (ηp^2^ = 0.107). Tuberculosis coinfection was associated with elevated sCD14 levels (coefficient, 0.11 log~10~ ng/mL per unit increase; 95% CI, .04--.18; *P* = .02), with an estimated medium effect size (ηp^2^ = 0.062). The association was found to be statistically significant (*P* \< .05) for some other factors, but all had small estimated effect sizes (ηp^2^ \< 0.06) ([Supplementary Tables 7](#sup9){ref-type="supplementary-material"} and [8](#sup10){ref-type="supplementary-material"}).

Discussion {#s10}
==========

In this large African HIV cohort, we found that all of the 8 measured plasma biomarkers were significantly elevated in untreated adults and decreased during ART-mediated viral suppression. Whereas 3 biomarkers, IL-6, CCL2, and CXCL9, normalized during suppressive ART, 5 biomarkers, CXCL10, LBP, CRP, sCD163, and sCD14, were still elevated, compared with the HIV-uninfected reference group. The pre-ART levels of each of the biomarkers were the strongest predictors of residual immune activation during ART. Before ART initiation, high viral load was associated with elevated CXCL10, and tuberculosis coinfection was associated with elevated sCD14. This study provides evidence of persistent monocyte/macrophage activation, inflammation, and microbial translocation in HIV-infected African adults during suppressive ART, extending data from Western countries. Residual immune dysregulation may have serious long-term health implications for the millions of Africans living with HIV, in terms of accelerated immune senescence, cardiovascular disease, and other serious non-AIDS diseases.

Residual CXCL10 elevation during ART could be driven by known or unmeasured coinfections, including tuberculosis, hepatitis C virus \[[@CIT0009]\], and hepatitis B virus \[[@CIT0010]\], and low-level HIV replication \[[@CIT0011]\]. Increased plasma sCD14 and sCD163 levels, markers of monocyte activation, during durable control of viremia have been reported elsewhere \[[@CIT0001]\]. LBP, known to accelerate binding of LPS, a cell wall component of gram-negative bacteria, to CD14 \[[@CIT0012]\], was also elevated during ART. These findings concur with a previous study in South Africa that found a limited effect of ART on reducing sCD14, tumor necrosis factor and plasma LPS, suggesting that persistent microbial translocation is a major force driving chronic inflammation in HIV-infected Africans receiving ART \[[@CIT0004]\]. Also in line with our findings, a recent study in Uganda found higher sCD14, intestinal fatty-acid binding protein and CRP levels in HIV-infected persons on ART, although, discordant with our study, they found women to have higher inflammation levels than men \[[@CIT0005]\]. In addition, we found that active tuberculosis coinfection at ART initiation was associated with elevated pre-ART levels of sCD14, which was largely mitigated during ART, probably due to the effect of concomitant anti-tuberculosis treatment. This extends on earlier findings in South Africa where HIV-infected individuals with tuberculosis coinfection were found to have elevated monocyte activation (sCD14) and inflammation (CRP, IL-6, and CXCL10) \[[@CIT0013]\].

CCL2, LBP, IL-6 and CRP were found to be differentially expressed in HIV-infected participants from the 5 countries during ART. Another recent study also found CCL2 and the interleukin 2 receptor alpha to be differentially expressed in HIV-infected participants across Uganda, Kenya, Tanzania, and Nigeria \[[@CIT0014]\]. This suggests that differences between populations and geographic locations,, such as host genetics, environmental factors, smoking status and other lifestyle factors, coinfections, and hygiene standards, could play a major role in patterns of immune activation in sub-Saharan Africa.

The main strengths of the study were the measurement of a broad panel of the most clinically relevant immune biomarkers \[[@CIT0001], [@CIT0007]\] in a large cohort with broad geographic coverage, while mitigating the effect of HIV replication. There are several study limitations. First, our study was not able to fully assess some factors that could affect immune dysregulation, particularly coinfections (eg, cytomegalovirus, hepatitis C virus, and helminths), smoking status, and host genetics. Similarly, information on the HIV-uninfected blood donors was limited to age, sex, and country, with potential for uncontrolled confounding factors \[[@CIT0015]\]. Second, we did not measure biomarkers beyond the first year of ART. However, studies have suggested that the main effect of ART on immune activation occurs in the first year, with possibly no further decrease during sustained viral suppression thereafter \[[@CIT0002]\].

In conclusion, suppressive ART only partially mitigated HIV-related immune activation in African adults, with persistent monocyte/macrophage activation, inflammation, and microbial translocation. These findings provide further support to earlier ART initiation and also highlight the urgency for further research in African populations to elucidate the critical immune pathways and their clinical implications and to explore opportunities for adjunct host-directed therapies to improve long-term prognosis.

Supplementary Data {#s11}
==================

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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